{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:16:01Z","timestamp":1790129761620,"version":"4.0.1"},"reference-count":70,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biology"],"abstract":"<jats:p>The repurposing of previously clinically approved drugs as an alternative therapeutic approach to treating disease has gained significant attention in recent years. A multitude of studies have demonstrated various and successful therapeutic interventions with these drugs in a wide range of neoplastic diseases, including multiple myeloma, leukaemia, glioblastoma, and colon cancer. Drug repurposing has been widely encouraged due to the known efficacy, safety, and convenience of already established drugs, allowing the bypass of the long and difficult road of lead optimization and drug development. Repurposing drugs in cancer therapy is an exciting prospect due to the ability of these drugs to successfully target cancer-associated genes, often dysregulated in oncogenic signalling pathways, amongst which are the classical cancer signalling pathways; WNT (wingless-related integration type) and Hippo signalling. These pathways play a fundamental role in controlling organ size, tissue homeostasis, cell proliferation, and apoptosis, all hallmarks of cancer initiation and progression. Prolonged dysregulation of these pathways has been found to promote uncontrolled cellular growth and malignant transformation, contributing to carcinogenesis and ultimately leading to malignancy. However, the translation of cancer signalling pathways and potential targeted therapies in cancer treatment faces ongoing challenges due to the pleiotropic nature of cancer cells, contributing to resistance and an increased rate of incomplete remission in patients. This review provides analyses of a range of potential anti-cancer compounds in drug repurposing. It unravels the current understanding of the molecular rationale for repurposing these drugs and their potential for targeting key oncogenic signalling pathways.<\/jats:p>","DOI":"10.3390\/biology13060386","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T05:19:49Z","timestamp":1716873589000},"page":"386","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Drug Repurposing: Exploring Potential Anti-Cancer Strategies by Targeting Cancer Signalling Pathways"],"prefix":"10.3390","volume":"13","author":[{"given":"Natalia","family":"Haddad","sequence":"first","affiliation":[{"name":"Department of Biomolecular Sciences, Kingston University London, Kingston-upon-Thames KT1 2EE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Magura","family":"Gamaethige","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Sciences, Kingston University London, Kingston-upon-Thames KT1 2EE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8733-7965","authenticated-orcid":false,"given":"Nadine","family":"Wehida","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Sciences, Kingston University London, Kingston-upon-Thames KT1 2EE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2102-7339","authenticated-orcid":false,"given":"Ahmed","family":"Elbediwy","sequence":"additional","affiliation":[{"name":"Department of Biomolecular Sciences, Kingston University London, Kingston-upon-Thames KT1 2EE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024, March 10). Cancer. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_4","first-page":"1","article-title":"Environmental factors inducing human cancers","volume":"41","author":"Parsa","year":"2012","journal-title":"Iran. J. Public Health"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"a006098","DOI":"10.1101\/cshperspect.a006098","article-title":"Signal transduction in cancer","volume":"5","author":"Sever","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.tranon.2022.101510","article-title":"Key signal transduction pathways and crosstalk in cancer: Biological and therapeutic opportunities","volume":"26","author":"Fu","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40364-021-00323-7","article-title":"The Wnt signaling pathway in tumorigenesis, pharmacological targets, and drug development for cancer therapy","volume":"9","author":"Wang","year":"2021","journal-title":"Biomark. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0959-8049(02)00040-0","article-title":"The APC gene in colorectal cancer","volume":"38","author":"Fodde","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1073\/pnas.0911220107","article-title":"LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy","volume":"107","author":"Liu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Rodrigues, R., Duarte, D., and Vale, N. (2022). Drug Repurposing in Cancer Therapy: Influence of Patient\u2019s Genetic Background in Breast Cancer Treatment. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084280"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10456-019-09688-8","article-title":"Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer","volume":"23","author":"Unterleuthner","year":"2020","journal-title":"Angiogenesis"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/modpathol.2017.15","article-title":"CTNNB1 (beta-catenin) mutation identifies low grade, early-stage endometrial cancer patients at increased risk of recurrence","volume":"30","author":"Kurnit","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1158\/0008-5472.CAN-17-3303","article-title":"Combined Mutation of Apc, Kras, and Tgfbr2 Effectively Drives Metastasis of Intestinal Cancer","volume":"78","author":"Sakai","year":"2018","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Ng, L.F., Kaur, P., Bunnag, N., Suresh, J., Sung, I.C.H., Tan, Q.H., Gruber, J., and Tolwinski, N.S. (2019). Wnt signalling in disease. Cells, 8.","DOI":"10.3390\/cells8080826"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Bian, J., Dannappel, M., Wan, C., and Firestein, R. (2020). Transcriptional Regulation of Wnt\/B-Catenin Pathway in Colorectal Cancer. Cells, 9.","DOI":"10.3390\/cells9092125"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fcell.2021.714746","article-title":"The emerging mechanisms of Wnt secretion and signaling in development","volume":"9","author":"Mehta","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ijc.33811","article-title":"Wnt pathway modulators in cancer therapeutics: An update on completed and ongoing clinical trials","volume":"150","author":"Neiheisel","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11154-006-9003-3","article-title":"Diseases of Wnt signaling","volume":"7","author":"Johnson","year":"2006","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Xiao, Y., and Dong, J. (2021). The Hippo Signaling Pathway in Cancer: A Cell Cycle Perspective. Cancers, 13.","DOI":"10.3390\/cancers13246214"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1146\/annurev-biochem-013118-111829","article-title":"The Hippo Pathway: Biology and Pathophysiology","volume":"88","author":"Ma","year":"2019","journal-title":"Annu. Rev. Biochem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.celrep.2018.10.001","article-title":"Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer","volume":"25","author":"Wang","year":"2018","journal-title":"Cell Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1530\/ERC-14-0456","article-title":"Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer","volume":"22","author":"Pecero","year":"2015","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41467-023-39527-w","article-title":"Cancer lineage-specific regulation of YAP responsive elements revealed through large-scale functional epigenomic screens","volume":"14","author":"Barbosa","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.devcel.2021.12.006","article-title":"YAP1 and PRDM14 converge to promote cell survival and tumorigenesis","volume":"57","author":"Kim","year":"2022","journal-title":"Dev. Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s43018-020-00150-z","article-title":"Single-cell analyses reveal YAP\/TAZ as regulators of stemness and cell plasticity in Glioblastoma","volume":"2","author":"Castellan","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1021\/acs.jmedchem.1c00804","article-title":"Inhibitors of the Hippo Pathway Kinases STK3\/MST2 and STK4\/MST1 Have Utility for the Treatment of Acute Myeloid Leukemia","volume":"65","author":"Bata","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nm.3562","article-title":"Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers","volume":"20","author":"Cottini","year":"2014","journal-title":"Nat. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ymthe.2021.08.029","article-title":"Non-canonical role of Hippo tumor suppressor serine\/threonine kinase 3 STK3 in prostate cancer","volume":"30","author":"Schirmer","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41420-023-01319-y","article-title":"Verteporfin reverses progestin resistance through YAP\/TAZ-PI3K-Akt pathway in endometrial carcinoma","volume":"9","author":"Wei","year":"2023","journal-title":"Cell Death Discov."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/mco2.375","article-title":"Targeting Hippo signaling in cancer: Novel perspectives and therapeutic potential","volume":"4","author":"Lv","year":"2023","journal-title":"MedComm"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncomms14058","article-title":"VGLL4 targets a TCF4-TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer","volume":"8","author":"Jiao","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"11717","DOI":"10.1073\/pnas.1120068109","article-title":"Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors","volume":"109","author":"Gurney","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.08.005","article-title":"Targeting the Wnt pathway in human cancers: Therapeutic targeting with a focus on OMP-54F28","volume":"146","author":"Le","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1758834013517414","article-title":"Tumor heterogeneity in the clinic: Is it a real problem?","volume":"6","author":"Janku","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4143\/crt.2022.078","article-title":"Challenges in the Use of Targeted Therapies in Non-Small Cell Lung Cancer","volume":"54","author":"Uprety","year":"2022","journal-title":"Cancer Res. Treat."},{"key":"ref_36","first-page":"127","article-title":"Translational bioinformatics methods for drug discovery and drug repurposing","volume":"13","author":"Ahamad","year":"2021","journal-title":"Adv. Ubiquitous Sens. Appl. Healthc."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/jphp.13273","article-title":"Drug repositioning: A brief overview","volume":"72","author":"Jourdan","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1134\/S1068162023020139","article-title":"Drug Repurposing: An Effective Tool in Modern Drug Discovery","volume":"49","author":"Kulkarni","year":"2023","journal-title":"Russ. J. Bioorganic Chem."},{"key":"ref_39","unstructured":"Badria, F.A. (2020). Drug Repurposing\u2014Hyposthesis, Molecular Aspects and Therapeutic Applications, IntechOpen."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7150\/ijbs.24612","article-title":"Review of Drug Repositioning Approaches and Resources","volume":"14","author":"Xue","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.semcancer.2020.03.011","article-title":"Drug rechannelling: A novel paradigm for cancer treatment","volume":"68","author":"Kaushik","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Badria, F.A. (2020). Drug Repurposing and Orphan Disease Therapeutics. Drug Repurposing\u2014Hypothesis, Molecular Aspects and Therapeutic Applications, IntechOpen.","DOI":"10.5772\/intechopen.83082"},{"key":"ref_43","first-page":"4","article-title":"DrugRepo: A novel approach to repurposing drugs based on chemical and genomic features","volume":"12","author":"Wang","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Hijazi, M.A., Gessner, A., and El-Najjar, N. (2023). Repurposing of Chronically Used Drugs in Cancer Therapy: A Chance to Grasp. Cancers, 15.","DOI":"10.3390\/cancers15123199"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s40001-023-01275-4","article-title":"Repurposing approved non-oncology drugs for cancer therapy: A comprehensive review of mechanisms, efficacy, and clinical prospects","volume":"28","author":"Chawla","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3389\/fonc.2020.562196","article-title":"Psychotropic Drugs Show Anticancer Activity by Disrupting Mitochondrial and Lysosomal Function","volume":"10","author":"Varalda","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_47","first-page":"2","article-title":"Cytotoxicity and reversal effect of sertraline, fluoxetine, and citalopram on MRP1- and MRP7-mediated MDR","volume":"14","author":"Kanner","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_48","first-page":"22","article-title":"SSRI Antidepressant Medications: Adverse Effects and Tolerability","volume":"3","author":"Ferguson","year":"2001","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/neurolint13030038","article-title":"Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review","volume":"13","author":"Edinoff","year":"2021","journal-title":"Neurol. Int."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Duarte, D., and Vale, N. (2022). Antidepressant Drug Sertraline against Human Cancer Cells. Biomolecules, 12.","DOI":"10.3390\/biom12101513"},{"key":"ref_51","first-page":"2","article-title":"Sertraline repositioning: An overview of its potential use as a chemotherapeutic agent after four decades of tumor reversal studies","volume":"16","author":"Sumida","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_52","first-page":"277","article-title":"Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice","volume":"33","author":"Zolokov","year":"2008","journal-title":"Int. J. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.advms.2023.06.001","article-title":"Sertraline as a potential cancer therapeutic approach: Biological relevance of TCTP in breast cancer cell lines and tumors","volume":"68","author":"Baldissera","year":"2023","journal-title":"Adv. Med. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/cmdc.202100528","article-title":"Revisiting the Molecular Interactions between the Tumor Protein TCTP and the Drugs Sertraline\/Thioridazine","volume":"17","author":"Malard","year":"2022","journal-title":"ChemMedChem"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12964-023-01096-2","article-title":"Serotonin acts through YAP to promote cell proliferation: Mechanism and implication in colorectal cancer progression","volume":"21","author":"Yu","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.bcp.2008.01.015","article-title":"Inhibitory effect of fluoxetine on lymphoma growth through the modulation of antitumor T-cell response by serotonin-dependent and independent mechanisms","volume":"75","author":"Frick","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.toxlet.2011.04.024","article-title":"Fluoxetine induces preventive and complex effects against colon cancer development in epithelial and stromal areas in rats","volume":"204","author":"Kannen","year":"2011","journal-title":"Toxicol. Lett."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/toxsci\/kfy143","article-title":"Fluoxetine Inhibits Canonical Wnt Signaling to Impair Embryoid Body Morphogenesis: Potential Teratogenic Mechanisms of a Commonly Used Antidepressant","volume":"165","author":"Marikawa","year":"2018","journal-title":"Toxicol. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.tips.2008.07.004","article-title":"Artemisinins: Their growing importance in medicine","volume":"29","author":"Krishna","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2217\/fon.13.228","article-title":"Use of artemisinin and its derivatives to treat HPV-infected\/transformed cells and cervical cancer: A review","volume":"10","author":"Goodrich","year":"2014","journal-title":"Future Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/ijc.22804","article-title":"Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt\/beta-catenin pathway","volume":"121","author":"Li","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Zhou, X., Suo, F., Haslinger, K., and Quax, W.J. (2022). Artemisinin\u2014Type Drugs in Tumor Cell Death: Mechanisms, Combination Treatment with Biologics and Nanoparticle Delivery. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020395"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/IGC.0b013e31824a67c9","article-title":"Selective Radiosensitization of Human Cervical Cancer Cells and Normal Cells by Artemisinin Through the Abrogation of Radiation-Induced G2Block","volume":"22","author":"Gong","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1748-717X-9-84","article-title":"Artemisinin derivative artesunate induces radiosensitivity in cervical cancer cells in vitro and in vivo","volume":"9","author":"Luo","year":"2014","journal-title":"Radiat. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1007\/s00204-019-02579-3","article-title":"Artemisinin suppresses hepatocellular carcinoma cell growth, migration and invasion by targeting cellular bioenergetics and Hippo-YAP signaling","volume":"93","author":"Li","year":"2019","journal-title":"Arch. Toxicol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and Cancer: Trigger, Mechanism, and Consequence","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/nature01322","article-title":"Inflammation and Cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"ref_68","first-page":"2","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Haider, M., Elsherbeny, A., Pittal\u00e0, V., Fallica, A.N., Alghamdi, M.A., and Greish, K. (2021). The Potential Role of Sildenafil in Cancer Management through EPR Augmentation. J. Pers. Med., 11.","DOI":"10.20944\/preprints202104.0679.v1"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.18632\/oncotarget.6749","article-title":"Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95","volume":"7","author":"Anindita","year":"2016","journal-title":"Oncotarget"}],"container-title":["Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-7737\/13\/6\/386\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:49:23Z","timestamp":1760107763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-7737\/13\/6\/386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":70,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["biology13060386"],"URL":"https:\/\/doi.org\/10.3390\/biology13060386","relation":{},"ISSN":["2079-7737"],"issn-type":[{"value":"2079-7737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]}}}